medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2016, Número 02

<< Anterior Siguiente >>

Ginecol Obstet Mex 2016; 84 (02)


Proporción LH-FSH y síndrome de ovario poliquístico: ¿prueba olvidada o no útil?

Saucedo de la Llata E, Moraga-Sánchez MR, Romeu-Sarrió A, Carmona- Ruiz IO

Idioma: Español
Referencias bibliográficas: 43
Paginas: 84-94
Archivo PDF: 498.75 Kb.


RESUMEN

Objetivo: identificar el valor predictivo de la proporción LH-FSH para el diagnóstico de síndrome de ovario poliquístico y su utilidad en los distintos fenotipos.
Material y Método: estudio descriptivo, comparativo, observacional y prospectivo de pacientes con síndrome de ovario poliquístico y controles. Todas las participantes respondieron un cuestionario y se les realizó un examen físico y ecográfico transvaginal. Se tomaron muestras de sangre para analizar marcadores metabólicos y concentración de hormonas. El síndrome de ovario poliquístico se diagnosticó con los criterios de Rotterdam.
Resultados: se estudiaron 267 mujeres y se diagnosticó síndrome de ovario poliquístico en 162. Se observaron diferencias con significación estadística en: HOMA, 1.43 ± 1.06, 2.09 ± 1.96 mUI/mL; testosterona total, 0.31 ± 0.14, 0.41 ± 0.19 mUI/mL y el índice de andrógenos libres, 1.17 ± 1.30, 1.69 ± 1.18 mUI/mL para el grupo control y grupo con síndrome de ovario poliquístico, respectivamente. La FSH se encontró en 6.55 ± 2.43 mUI/mL en el grupo control y 5.30 ± 1.66 mUI/mL en el grupo con síndrome de ovario poliquístico (p= 0.001); LH, 4.34 ± 2.12 mUI/mL en el grupo control; 6.36 ± 4.61 mUI/mL en el grupo con síndrome de ovario poliquístico (p= 0.001). La relación LH-FSH para el grupo control es de 0.71 ± 0.39 mUI/mL y para el grupo con síndrome de ovario poliquístico de 1.25 ± 0.85 mUI/mL, p= 0.001. Se observó correlación de la proporción LH-FSH con la cuenta total de folículos antrales (p ‹0.001) y con la resistencia a la insulina (p=0.022)
Conclusiones: la proporción LH-FSH sirve como parámetro de apoyo, pero no de diagnóstico del síndrome de ovario poliquístico. Aunque nosotros observamos mayor correlación de este parámetro con la resistencia a la insulina, no debemos olvidar su importante asociación con el hiperandrogenismo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health carerelated economic burden of the polycystic ovary syndrome during the reproductive life span. The Journal of clinical endocrinology and metabolism. 2005;90(8):4650-8.

  2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. The Journal of clinical endocrinology and metabolism. 1999;84(6):1897-9.

  3. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. The Journal of clinical endocrinology and metabolism. 2006;91(1):2-6.

  4. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Journal of endocrinological investigation. 2006;29(3):270-80.

  5. Amsterdam EA-SrPCWG. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Human reproduction. 2012;27(1):14-24.

  6. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of clinical endocrinology and metabolism. 1998;83(9):3078-82.

  7. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of clinical endocrinology and metabolism. 2000;85(7):2434-8.

  8. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of clinical endocrinology and metabolism. 2004;89(6):2745-9.

  9. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Human reproduction. 2014.

  10. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clinical endocrinology. 1999;51(6):779-86.

  11. Practice Committee of American Society for Reproductive M. Current evaluation of amenorrhea. Fertility and sterility. 2008;90(5 Suppl):S219-25.

  12. McCartney CR, Gingrich MB, Hu Y, Evans WS, Marshall JC. Hypothalamic regulation of cyclic ovulation: evidence that the increase in gonadotropin-releasing hormone pulse frequency during the follicular phase reflects the gradual loss of the restraining effects of progesterone. The Journal of clinical endocrinology and metabolism. 2002;87(5):2194- 200.

  13. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG : an international journal of obstetrics and gynaecology. 2006;113(10):1210-7.

  14. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. The Journal of clinical endocrinology and metabolism. 1991;73(4):811-7.

  15. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 1997;82(7):2248-56.

  16. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility. 2004;81(1):19-25.

  17. Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction. 2004;19(1):41-7.

  18. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122(1-3):42- 52.

  19. Kauffman RP, Baker VM, DiMarino P, Castracane VD. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertility and sterility. 2006;85(4):1010-6.

  20. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2008;18(7):511-8.

  21. Suresh S, Vijayakumar T. Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism. Indian J Clin Biochem. 2015;30(3):345-50.

  22. Baldani DP, Skrgatic L, Simunic V, Zlopasa G, Canic T, Trgovcic I. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in the Croatian population. Coll Antropol. 2013;37(2):477-82.

  23. Barth JH, Field HP, Yasmin E, Balen AH. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography- tandem mass spectrometry and analysis by receiver operator characteristic plots. European journal of endocrinology - European Federation of Endocrine Societies. 2010;162(3):611-5.

  24. Hendriks ML, Brouwer J, Hompes PG, Homburg R, Lambalk CB. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo-amenorrhoea. Reproductive biomedicine online. 2008;16(6):765-71.

  25. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human reproduction. 2006;21(1):80-9.

  26. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. The Journal of clinical endocrinology and metabolism. 1961;21:1440-7.

  27. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. American journal of obstetrics and gynecology. 1981;140(7):815-30.

  28. Reingold SB, Rosenfield RL. The relationship of mild hirsutism or acne in women to androgens. Archives of dermatology. 1987;123(2):209-12.

  29. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Human reproduction. 2011;26(11):3123-9.

  30. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285-93.

  31. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome December 3–5, 20122012 01-03-2014. Available from: http:--prevention.nih.gov-workshops- 2012-pcos-docs-PCOS_Final_Statement.pdf.

  32. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European journal of endocrinology - European Federation of Endocrine Societies. 2014;171(4):P1-29.

  33. Atiomo WU, Khalid S, Ziauddin A, Tooth D, Layfield R. Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome. Expert review of proteomics. 2009;6(5):469-99.

  34. Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology. 1997;15(2):111- 22.

  35. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clinical obstetrics and gynecology. 2003;46(2):325-40.

  36. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Human reproduction update. 2005;11(4):357-74.

  37. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and sterility. 2004;81(1):114-9.

  38. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism: clinical and experimental. 1999;48(2):167-72.

  39. Turhan NO, Toppare MF, Seckin NC, Dilmen G. The predictive power of endocrine tests for the diagnosis of polycystic ovaries in women with oligoamenorrhea. Gynecologic and obstetric investigation. 1999;48(3):183-6.

  40. Escobar-Morreale HF, Asuncion M, Calvo RM, Sancho J, San Millan JL. Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. European journal of endocrinology - European Federation of Endocrine Societies. 2001;145(5):619-24.

  41. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. The Journal of clinical endocrinology and metabolism. 2010;95(9):4399-405.

  42. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHREASRM- Sponsored 3rd PCOS Consensus Workshop Group. Fertility and sterility. 2012;97(1):28-38 e25.

  43. Ehrmann DA. Polycystic ovary syndrome. The New England journal of medicine. 2005;352(12):1223-36.




2020     |     www.medigraphic.com